The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets ...

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

This may be readily induced with intensive bronchodilator or steroid (cortisone, cortisol, prednisone or prednisolone) therapy, singly or in combination. This, we believe, is one of the essential ...

Rituximab may be an effective therapeutic option in the management of severe necrotizing scleritis associated with AAV.

Prednisolone can be used in place of prednisone in equivalent doses. Follow–up recommendations: serum AST or ALT, total bilirubin and γ –globulin levels at 3–week intervals during ...

and prednisone or prednisolone was associated with a median OS of 42.1 months, compared to 34.7 months with abiraterone plus placebo. That 7.4 month difference did not, however, achieve ...

Prednisone is converted to prednisolone within the liver, and the unbound fraction of prednisolone is responsible for side effects. [18] Reduced availability of the albumin carrier for ...

The FDA approval draws on a phase 3 trial of Akeega, called MAGNITUDE, which showed that the addition of niraparib to Zytiga plus prednisone or prednisolone significantly improved radiographic ...